Aktive Positionen von Thomas Burke
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Rovermed Biosciences LLC
 Rovermed Biosciences LLC BiotechnologyHealth Technology Rovermed Biosciences LLC develops precision targeted nanocapsule technology aimed at delivering life saving drugs to the most challenging disease sites. The company was founded in 2016 and is headquartered in St. Cloud, MN. | Direktor/Vorstandsmitglied | - | - |
| Vorsitzender | - | - | |
Hennepin Life Sciences LLC
 Hennepin Life Sciences LLC Pharmaceuticals: MajorHealth Technology Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN. | Direktor/Vorstandsmitglied | - | - |
| Vorstandsvorsitzender | - | - |
Karriereverlauf von Thomas Burke
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Director/Board Member | 2 |
| Chairman | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Rovermed Biosciences LLC
Rovermed Biosciences LLC BiotechnologyHealth Technology Rovermed Biosciences LLC develops precision targeted nanocapsule technology aimed at delivering life saving drugs to the most challenging disease sites. The company was founded in 2016 and is headquartered in St. Cloud, MN. | Health Technology |
Hennepin Life Sciences LLC
Hennepin Life Sciences LLC Pharmaceuticals: MajorHealth Technology Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN. | Health Technology |
- Börse
- Insiders
- Thomas Burke
- Erfahrung
